Closed-end funds are an asset management company's dream business. The assets are almost completely "stuck" to the fund (unless an activist forces the fund to 'open') regardless of performance. But it should come as no surprise that many of these funds end up disappointing investors. When investors become disappointed they sell their shares in the closed-end fund on their respective exchange and move on, regardless of the fund's price relative to net asset value.
It's this system that forces many closed-end funds to trading below their net asset value. In fact, 82% of closed-end funds now trade for a discount to their net asset value, a significant increase since March (64%) according to an interesting article [subscription required] in today's Wall Street Journal.
I'd put "do not buy a closed-end fund at its IPO" as one of my core rules of investing. Many times investors are forced to pay a premium above net asset value when the fund first begins trading -- a move that investors regret most of the time.
However, that doesn't mean there's no opportunity in closed-end funds after they begin trading. In fact, funds at a deep discount to net asset value can often be very enticing value situations. When looking at funds below NAV I typically favor newly-discounted names (because it's often only due to one or two large sellers) or situations in which an activist is trying to convert the fund to being 'open-end' thus reverting the share price to its NAV.
Note: Premiums/discounts to net asset values can be found using ETFConnect.com.
Last updated: February 13, 2012: 02:29 PM
Hot Stocks
DailyFinance Headlines
- 3 Keys to a Great Balance Transfer Card (and 1 Card That Offers Them)
- Is It Already 'The End' for E-Book Readers?
- Retail Stocks Are for Suckers: Why Their Rally Won't Last
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
Benzinga Headlines
- Airlines the Latest to Suffer Euro Crisis Blues
- Internet-Hungry Consumers Force Vodafone to Consider a C&W Offer
- Seven Japanese Stocks Up More Than 10% Year to Date
- Does the 2012 Election Really Matter for the Economy?
- Michigan Consumer Sentiment Index Drops
TheFlyOnTheWall.com Headlines
- NTS, Inc. announces $1.35M bond buyback plan
- Jabil Circuit target raised to $32 from $24 at Argus
- NYSE market internals summary
- NASDAQ market internals summary
- Honda looks to double car production in Europe, Financial Times reports
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- 3 Keys to a Great Balance Transfer Card (and 1 Card That Offers Them)
- Is It Already 'The End' for E-Book Readers?
- Retail Stocks Are for Suckers: Why Their Rally Won't Last
- Suddenly, Amazon Doesn't Love Its Moms Anymore
- How State Taxes Put a Bigger Pinch on the Poor
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
5-Hour Energy: A Success Equal Parts Caffeine, Chemistry and…
Suddenly, Amazon Doesn't Love Its Moms Anymore

